SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment

SAB Biotherapeutics Inc. (NASDAQ:SABS) is one of the 10 best stocks under $10 that could triple.

On July 7, SAB Biotherapeutics Inc. (NASDAQ:SABS) and Breakthrough T1D, a leading research and advocacy firm for type 1 diabetes, disclosed that Breakthrough T1D has awarded a research grant to Michael J. Haller, M.D., Chief Pediatric Endocrinologist and Professor at the University of Florida. This grant has been given to support the PRISE-hATG, which is a clinical assessment of SAB-142 in Stage 3 T1D patients, who are somewhere between 100 days and 2 years away from disease diagnosis.

Copyright: dolgachov / 123RF Stock Photo

This study aims to evaluate whether SAB-142 has the capability to preserve endogenous C-peptide and regulate immune responses. It applies to individuals who carry residual beta cell activity after the initial 100 days following the diagnosis of Stage 3.

Back on June 24, Eliana Merle from Barclays initiated coverage of the stock with an Overweight rating. She set a target price of $13, which translates into an upside potential of more than 240% at the current level.

Merle noted that SAB-142 carries a lucrative opportunity as a disease-altering cure for type 1 diabetes. Going forward, she is anticipating the immunotherapy’s Phase 2b data to be a key catalyst for the stock, with results expected sometime during the second half of 2027.

SAB Biotherapeutics Inc. (NASDAQ:SABS) is a clinical-stage biopharmaceutical company that focuses on the development of human polyclonal immunotherapeutic antibodies. Its main product candidate is SAB-142 for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.

While we acknowledge the risk and potential of SABS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SABS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.